A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

StatusCompleted
PhasePhase 1/2
SponsorAkeso
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 5 entries Show 7 more changesShow less
    • Trial status changed: Unknown → Completed
    • Final enrollment: 35 participants (planned 294)
    • Primary completion date changed from estimate of Jul 2026 to Apr 20, 2026
    • Start date changed from estimate of Sep 10, 2024 to Sep 30, 2024
    • Interventions modified
    • Eligibility criteria expanded, about 16 words
    • Site contact updated
  2. Changed Registry marked status Unknown; last known: Not Yet Recruiting
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Akeso
97 trials monitored
See 1 trial at risk
Gastric Cancer
1,281 trials monitored
See 61 trials at risk
Phase Ib/II clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma
Trial Details
NCT Number NCT06586294
Lead Sponsor Akeso
Conditions
(from sponsor)		 Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov